Latest Headlines

Latest Headlines

3-D printed tumor mimics cancer better than 2-D model

A team of researchers from the U.S. and China has used 3-D printing to create a realistic model of a cancerous tumor.

Exact Sciences raises nearly $120M, focused on a hoped-for 2014 launch of its colon cancer Dx

Exact Sciences President and CEO Kevin Conroy previously promised that 2014 will be all about getting the company's Cologuard colon cancer test to market. Now, the company will be armed with close to $120 million to get the job done.

Scripps scientists say new biomarker for various cancers might be more useful

Another newly discovered biomarker is now under consideration as a tool to help evaluate and treat disease. When the body expresses it, it appears to be tied to better survival chances in both non-small cell lung cancer and head and neck cancer.

Roche's Ventana pairs with Genmab on yet another companion Dx deal

Roche's Ventana Medical Systems will work with Denmark's Genmab to come up with a companion diagnostic test to be paired with a targeted anticancer drug now in development.

Foundation Medicine will develop a test for Clovis' ovarian cancer drug

Foundation Medicine will develop a companion diagnostic test for use with a Clovis Oncology drug now in mid-stage clinical trials to treat patients with ovarian cancer.

Maryland Dx startup raises $2.8M to advance cancer genome analysis tech

Maryland's Personal Genome Diagnostics raised $2.8 million to help advance development of its cancer genome analysis technology. Separately, the company is launching its new METDetect Assay that helps spot alterations in the MET gene in circulating tumor DNA directly from a patient's blood.

Finding: 2 biomarkers for head and neck cancer can help predict radiation therapy resistance

International researchers led by Michigan's Beaumont Health System discovered two biomarkers that helped predict resistance to radiation therapy for patient's with squamous cell cancer of the head and neck.

CTC levels could provide a prostate cancer survival clue

New research supports the use of a circulating tumor cell blood test, rather than the standard PSA biomarker diagnostic, to predict a patient's odds of surviving prostate cancer.

For 2014, Trovagene plots multiple ways to expand the reach of its Dx cancer tech

Trovagene made real progress in 2013, launching its urine-based cancer test and expanding or forging collaboration deals with research facilities and diagnostic and pharmaceutical companies. But financial results for the year remained a mixed bag.

Analysts applaud as Bristol-Myers preps a PhIII study for PD-1 cancer combo

The last 24 hours offered an important lesson over just how closely analysts and investors are tracking every movement on the immunotherapy front in cancer R&D.